Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodexa Pharmaceuticals plc (NASDAQ: BDRX) SEC filings page on Stock Titan provides direct access to the company’s US regulatory disclosures as a foreign private issuer. Biodexa reports to the Securities and Exchange Commission primarily through Form 20-F for its annual report and Form 6-K for current reports on material developments. These filings document clinical, regulatory and financing milestones for its lead programs eRapa, tolimidone and MTX110.
Recent Form 6-K filings describe key events such as the approval of a Clinical Trial Application (CTA) by the European Medicines Agency for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), enrollment of the first patients into that trial, and related press releases. Other 6-Ks outline corporate actions including ADR ratio changes, results of the company’s annual general meeting, and details of capital-raising transactions like equity line of credit arrangements and a best-efforts public offering of ADS Units and pre-funded units with accompanying Series L warrants.
Through these filings, investors can review information on offering structures, warrant terms, use of proceeds, grant funding supporting the eRapa FAP program, and updates on cash and cash equivalents at specified dates. The exhibits attached to 6-Ks often include full text of securities purchase agreements, placement agency agreements and warrant forms, providing additional detail on financing terms.
Stock Titan enhances access to BDRX filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents such as current reports and registration-related materials. Users can quickly understand how new financings, clinical trial milestones or regulatory approvals described in Form 6-K may relate to Biodexa’s broader development strategy, while still having the option to read the full SEC documents for complete context.
Biodexa Pharmaceuticals files a prospectus supplement to its existing Form F-1 to incorporate a new Form 6-K describing an exclusive license and collaboration with Otsuka Pharmaceutical for MTX240, a Phase 1-ready molecular glue therapeutic candidate initially aimed at treating gastrointestinal stromal tumors (GIST).
Under the agreement, Biodexa receives exclusive rights to develop, manufacture and commercialize MTX240 worldwide excluding Japan, while Otsuka retains Japanese rights. Biodexa made an upfront payment and Otsuka is entitled to one-time development and regulatory milestones, tiered mid-single-digit royalties on net sales, and a share of any sublicense income.
The attached press release explains that MTX240 (OPB-171775) uses a molecular glue mechanism to induce apoptosis in GIST cells through a pathway independent of KIT signaling and has shown dose-dependent anti-tumor activity in tyrosine kinase inhibitor–resistant patient-derived xenograft models, targeting a population with significant unmet medical need.
Biodexa Pharmaceuticals PLC filed a prospectus supplement for the resale by a selling shareholder of up to 341,352,000,000 ordinary shares, represented by 3,413,520 American Depositary Shares. The supplement also incorporates a Form 6-K describing a new licensing deal.
The company entered into an exclusive, worldwide (excluding Japan) license and collaboration agreement with Otsuka Pharmaceutical for OPB-171775, a Phase 1-ready molecular glue therapeutic to be developed as MTX240 for gastrointestinal stromal tumors. Biodexa will handle development, manufacturing, and commercialization outside Japan, while Otsuka keeps Japanese rights.
Otsuka received an upfront payment and may receive one-time development and regulatory milestones, plus tiered mid-single-digit royalties on net sales and a share of any sublicense income. MTX240 is backed by composition-of-matter patents in major territories extending through 2037.
Biodexa Pharmaceuticals has entered an exclusive license and collaboration agreement with Otsuka Pharmaceutical, gaining worldwide rights outside Japan to develop, manufacture and commercialize OPB-171775, now called MTX240, a Phase 1-ready molecular glue drug candidate for gastrointestinal stromal tumors (GIST).
MTX240 uses a novel mechanism by bringing PDE3a and SLFN12 proteins together in GIST cells to trigger apoptosis through a pathway independent of KIT signaling, aiming to overcome resistance to existing tyrosine kinase inhibitors. In resistant patient-derived xenograft mouse models, MTX240 showed dose-dependent anti-tumor activity.
Biodexa will handle development and commercialization in its territory and has paid an upfront fee, with Otsuka eligible for development and regulatory milestones and mid-single digit tiered royalties. MTX240 is covered by composition of matter patents in major regions through 2037.
Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC and Hal Mintz report a 9.9% beneficial ownership stake in Biodexa Pharmaceuticals Plc ADSs. The filing states they collectively beneficially own 217,600 ADSs, with shared power to vote and dispose of all of these securities and no sole voting or dispositive power. Each reporting person lists the same 217,600 ADSs and 9.9% of the class as their beneficial ownership.
The group certifies that the ADSs were not acquired and are not held for the purpose of changing or influencing control of Biodexa Pharmaceuticals Plc, and that they are not participating in any transaction with that purpose or effect, other than potential activities tied to a nomination under the specified proxy rule.
Biodexa Pharmaceuticals PLC has appointed Fiona Sharp as Chief Financial Officer, Corporate Secretary and member of the Board of Directors, effective January 5, 2026. She will serve as a director until the company’s annual general meeting in 2026, while Stephen Stamp continues as Chief Executive Officer after relinquishing the CFO and Corporate Secretary roles.
Sharp, aged 57, has been the company’s Group Financial Controller since December 2019 and previously held senior finance roles at Hywell DDA University Health Board and Chime Communications Limited. The company states that she has no family relationships with existing directors or executives, no selection arrangements with other parties, and no reportable transactions with the company. The appointment information is incorporated by reference into Biodexa’s existing Form S-8 and Form F-3 registration statements.
Biodexa Pharmaceuticals is registering 929,878,200,000 Ordinary Shares, in the form of American Depositary Shares (Depositary Shares), for a best-efforts public offering. The deal comprises 157,000 Units at $3.28 per Unit, each with one Depositary Share and two Series L Warrants, plus up to 2,891,781 Pre-Funded Units at $3.2799 each, with a Pre-Funded Warrant and two Series L Warrants. Each Series L Warrant is immediately exercisable at $3.28 for five years; each Pre-Funded Warrant is exercisable at $0.0001 per Depositary Share without expiry, subject to 4.99% or 9.99% beneficial ownership caps.
If all Units are sold, Biodexa estimates net proceeds of about $8.75 million, to be used to fund its development programs, working capital and general corporate purposes. Ordinary Shares outstanding are expected to rise from 68,178,708,922 to 83,878,708,922 after the offering, before any warrant exercises. The company highlights that this equity raise and potential future warrant exercises may significantly dilute existing holders and pressure the trading price.
Biodexa Pharmaceuticals PLC filed a prospectus supplement tied to a resale registration for up to 341,352,000,000 ordinary shares, represented by 3,413,520 American Depositary Shares. The company also describes a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including warrants with an exercise price of $3.28 per ADS. Net proceeds from this offering are expected to be about $8.75 million, to fund development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported unaudited cash and cash equivalents of £2.79 million and notes that, after the offering and before any warrant exercises, 83,878,708,922 ordinary shares will be outstanding.
Biodexa Pharmaceuticals filed a prospectus supplement covering the resale by existing shareholders of up to 109,800,000 ordinary shares represented by 1,098 American Depositary Shares. The company also commenced a best efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including one ADS or pre-funded warrant plus two Series L warrants, at combined prices of $3.28 and $3.2799 per unit. Net proceeds from this offering are expected to be approximately $8.75 million to fund development programs, working capital and other general corporate purposes, with closing anticipated on or about December 19, 2025. As of September 30, 2025, cash and cash equivalents were £2.79 million, and after the offering the company expects to have 83,878,708,922 ordinary shares outstanding, assuming no warrant exercises.
Biodexa Pharmaceuticals PLC files a prospectus supplement covering the resale of up to 171,700,000 ordinary shares, represented by 1,717 American Depositary Shares (ADSs). Alongside this, the company has launched a best-efforts public offering of 157,000 ADS units and 2,891,781 pre-funded units, each unit including warrants. The offering is expected to generate approximately $8.75 million in net proceeds, which the company plans to use to fund its development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported cash and cash equivalents of £2.79 million, and assuming the offering closes with no warrant exercises, it will have 83,878,708,922 ordinary shares outstanding.
Biodexa Pharmaceuticals PLC supplements its resale prospectus covering up to 4,349,000,000 ordinary shares, represented by 43,490 American Depositary Shares (ADSs), that may be sold from time to time by existing shareholders. Alongside this, the company has begun a best efforts public offering of 157,000 ADS units, each with one ADS and two Series L warrants, and 2,891,781 pre-funded units, each with a pre-funded warrant and two Series L warrants, at combined prices of $3.28 and $3.2799 per unit, respectively.
The offering is expected to generate approximately $8.75 million in net proceeds, which the company plans to use for development programs, working capital and general corporate purposes. As of September 30, 2025, Biodexa reported cash and cash equivalents of £2.79 million83,878,708,922 ordinary shares outstanding. New Series L and pre-funded warrants carry exercise caps at 4.99% or 9.99% beneficial ownership to limit concentration.